EU approves skin cancer fighting drug: Roche

February 20, 2012

Swiss drug giant Roche said on Monday it had been given European Union approval for its treatment to fight a highly aggressive form of skin cancer.

The European Commission gave the green light to Zelboraf, a drug used to treat adults with BRAF V600 mutation-positive unresectable or , the company announced in a statement.

If diagnosed early is generally curable but when it spreads to other parts of the body it is the deadliest form of .

Currently only one in four people lives for more than a year following diagnosis.

US approved Zelboraf in August last year, with Roche describing initial sales as "very encouraging."

The group recorded Zelboraf sales worth 31 million Swiss francs (25.7 million euros) in 2011.

The treatment, already approved by Switzerland, Brazil and Canada among others, has "revolutionised melanoma treatment," said analysts at the Zurich Cantonal Bank (ZKB).

Roche said the drug allows people to live significantly longer, with trials showing the risk of death was reduced by 63 percent for people who received Zelboraf compared to those who received standard first-line treatment.

Explore further: US approves new drug against skin cancer

Related Stories

US approves new drug against skin cancer

August 17, 2011

A breakthrough drug that could extend survival in some patients with advanced skin cancer was approved on Wednesday by US regulators, offering the first new treatment for melanoma in 13 years.

Recommended for you

Study identifies genomic features of cervical cancer

January 23, 2017

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies ...

Opinion: How dangerous is burnt toast?

January 23, 2017

A new campaign is warning people that burning some food, such as toast, is a potential cancer risk. Here, the evidence for this claim is explored by David Spiegelhalter, Professor of the Public Understanding of Risk at the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.